+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Schizophrenia Therapeutics Market by Type, Therapeutic Class, Mechanism of Action, Formulation Type, End Users, Patient Settings, Patient Demographics - Global Forecast to 2030- Product Image
Schizophrenia Therapeutics Market by Type, Therapeutic Class, Mechanism of Action, Formulation Type, End Users, Patient Settings, Patient Demographics - Global Forecast to 2030- Product Image
Sale

Schizophrenia Therapeutics Market by Type, Therapeutic Class, Mechanism of Action, Formulation Type, End Users, Patient Settings, Patient Demographics - Global Forecast to 2030

  • PDF Icon

    Report

  • 183 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6012570
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Schizophrenia Therapeutics Market grew from USD 5.89 billion in 2024 to USD 6.21 billion in 2025. It is expected to continue growing at a CAGR of 5.49%, reaching USD 8.12 billion by 2030.

Setting the Stage for Schizophrenia Therapeutics

The landscape of schizophrenia therapeutics has entered a pivotal phase marked by an unprecedented fusion of clinical innovation and patient-focused care models. This executive summary delivers a concise yet comprehensive exploration of the forces shaping treatment pathways, market dynamics, and strategic imperatives. Through an integrated review of evolving therapeutic modalities, regulatory developments, and stakeholder priorities, readers will emerge with a clear understanding of current challenges and emerging opportunities.

Anchored in rigorous research and expert perspectives, this overview distills key findings without overwhelming readers with technical minutiae. It highlights the technological, policy, and patient-driven trends that demand attention from developers, care providers, and investors alike. By synthesizing multidimensional insights, the summary paves the way for evidence-based decisions that can accelerate progress toward more effective, accessible solutions for individuals living with schizophrenia.

Emerging Forces Redefining Treatment Paradigms

The past decade has witnessed fundamental shifts that are rewriting the rules of engagement in schizophrenia care. Rapid advances in digital therapeutics are enabling remote monitoring and personalized interventions, while breakthroughs in immunopsychiatry offer novel pathways for addressing the disorder’s complex biology. Real-world evidence platforms have emerged as critical enablers of faster, more efficient clinical insights, reducing development timelines and fostering adaptive trial designs.

Regulatory agencies are responding to these innovations by streamlining approval processes for therapies that demonstrate tangible patient benefits. Simultaneously, healthcare systems are emphasizing integrated models that bridge pharmacological and non-pharmacological approaches, recognizing that optimal outcomes often arise from a holistic treatment paradigm. This confluence of science, policy, and patient-centric care is creating a fertile environment for the next generation of schizophrenia solutions.

Assessing the 2025 United States Tariff Consequences

In 2025, newly implemented tariffs in the United States introduced a complex layer of cost considerations for stakeholders across the supply chain. Manufacturers confronted increased expenses for imported active pharmaceutical ingredients and specialized excipients, prompting a reexamination of sourcing strategies and pricing models. These cost pressures have been particularly acute for smaller biotechs, which have fewer leverage points in negotiations and more constrained margins.

At the same time, companies have responded by forging strategic alliances to secure stable supply channels and by enhancing local manufacturing capabilities. Payers are carefully evaluating formulary positions, balancing the need for innovation against the imperatives of affordability and access. As these dynamics continue to unfold, the landscape for schizophrenia therapeutics in the U.S. is adapting in real time, with implications for product launch sequencing, reimbursement discussions, and investment priorities.

Unveiling the Nuances of Market Segmentation

Insights into treatment modalities reveal a nuanced interplay between pharmacological and non-pharmacological interventions. Cognitive-behavioral therapy, electroconvulsive therapy, and family therapy have solidified their roles as complementary approaches that amplify the impact of injectable and oral medications. This blended model underscores the importance of holistic care pathways that address both neurochemical and psychosocial dimensions of schizophrenia.

Examining therapeutic classes uncovers a clear evolution within antipsychotics as first-generation agents give way to second-generation molecules that offer improved side-effect profiles. Mood stabilizers and selective serotonin reuptake inhibitors also maintain critical roles in managing comorbid conditions, reflecting the shift toward personalized regimens tailored to individual symptom clusters and tolerability thresholds.

Mechanism of action segmentation highlights the continued dominance of dopamine receptor antagonists alongside emerging interest in glutamate modulators and serotonin-dopamine activity modulators. These novel mechanisms promise to tackle treatment-resistant cases by intervening in underexplored neurochemical pathways, signaling a new frontier in drug development.

Formulation type insights point to growing demand for patient-friendly delivery formats. Inserts and patches, liquid solutions, and solid tablets each offer distinct advantages in adherence, dosing flexibility, and tolerability. Optimizing the patient experience through formulation innovations remains a key differentiator in product strategy.

The end user environment spans homecare settings, hospitals, mental health clinics, and research institutes, each presenting unique decision criteria and operational challenges. Tailoring engagement strategies to the specific needs of these care venues is essential for maximizing uptake and ensuring continuity of care.

Patient settings reflect a spectrum of clinical intensity, from inpatient stabilization units to outpatient programs focused on community reintegration. Success in each context requires alignment of therapy characteristics with care protocols and resource availability.

Demographic considerations reveal distinct priorities across adult, geriatric, and pediatric populations. Age-specific safety profiles, dosing strategies, and support services must be integrated into product development and commercialization plans to address the full spectrum of patient needs.

Divergent Opportunities Across Global Regions

The Americas region continues to lead in clinical research activity and commercialization speed, driven by robust investment ecosystems and established reimbursement frameworks. North American policymakers are increasingly receptive to value-based contracting models that reward demonstrable improvements in quality of life and functional outcomes.

In Europe, the Middle East, and Africa, market entry strategies must navigate diverse regulatory landscapes and heterogeneous healthcare infrastructures. Western Europe’s progressive regulatory agencies have accelerated approvals for innovative agents, while emerging markets across the Middle East and North Africa prioritize scalable solutions that can alleviate resource constraints.

Asia-Pacific presents a dynamic tapestry of growth opportunities, from advanced markets in Japan and Australia to rapidly expanding healthcare systems in Southeast Asia. Local partnerships and licensing agreements have emerged as effective means to address regional variations in patient demographics, distribution networks, and pricing sensitivities.

Competitive Dynamics Among Leading Innovators

Leading players in schizophrenia therapeutics are deploying a mix of internal R&D investments and external collaborations to sustain their innovation engines. Pharmaceutical titans are broadening their portfolios through targeted acquisitions of specialist biotechs that offer disruptive assets in early development stages. Meanwhile, niche innovators focus on next-generation mechanisms of action and digital health tools to carve out differentiated positions.

Strategic alliances between global and regional entities enhance market access and accelerate clinical validation efforts. Companies with robust manufacturing infrastructures are forging supply partnerships to mitigate tariff impacts and ensure consistent product availability. Digital therapeutics providers are also forming coalitions with traditional drug developers to integrate app-based interventions into holistic treatment regimens.

The competitive landscape rewards agility and foresight, with success increasingly tied to the ability to anticipate patient needs, adapt to evolving regulations, and leverage real-world data for continuous improvement.

Strategic Pathways for Market Leadership

Industry leaders should prioritize investment in digital transformation, building platforms that support remote monitoring, adaptive dosing, and real-world data collection. Expanding non-pharmacological offerings will strengthen value propositions and address growing demand for integrated care models. Engaging early with payers through outcome-based contracts can secure favorable formulary positions and foster collaborative relationships.

Supply chain resilience must be reinforced by diversifying sourcing strategies and enhancing manufacturing flexibility. Stakeholders should pursue strategic partnerships with regional specialists to navigate tariff-related complexities and meet localized patient needs. Embracing patient-centered design principles in formulation development will optimize adherence and satisfaction across demographic segments.

Finally, forging cross-sector collaborations with academic institutions, advocacy organizations, and technology firms will accelerate innovation and amplify the impact of therapeutic advances on patient outcomes.

Robust Methodology Underpinning Our Analysis

This analysis is grounded in a comprehensive methodology that integrates in-depth secondary research with primary interviews of key opinion leaders, clinicians, and payers. Data triangulation ensures the validation of qualitative insights against quantitative evidence, while iterative peer reviews maintain the highest standards of accuracy and relevance.

Global regulatory databases and proprietary trial registries were systematically analyzed to map clinical pipelines and approval trajectories. Market dynamics were further contextualized through interactive workshops with stakeholders representing diverse care settings and geographic regions. Ethical guidelines and data privacy protocols underpinned every research phase, ensuring that findings reflect a balanced and transparent perspective.

Distilling Insights into Market Realities

Schizophrenia therapeutics stand at the threshold of transformative progress, driven by converging advances in pharmacology, digital health, and patient-centered care. While cost pressures and regulatory complexities present ongoing challenges, the strategic opportunities are clear for those who embrace innovation and collaboration.

By synthesizing segmentation insights, regional trends, and competitive dynamics, this executive summary equips decision-makers with a cohesive view of the landscape. The path forward demands agility, strategic foresight, and a relentless focus on outcomes that matter most to patients and healthcare systems alike.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Type
    • Non-Pharmacological Therapies
      • Cognitive-Behavioral Therapy (CBT)
      • Electroconvulsive Therapy (ECT)
      • Family Therapy
    • Pharmacological Therapies
      • Injectable Medications
      • Oral Medications
  • Therapeutic Class
    • Antipsychotics
      • First-Generation Antipsychotics
      • Second-Generation Antipsychotics
    • Mood Stabilizers
    • Selective Serotonin Reuptake Inhibitors
  • Mechanism of Action
    • Dopamine Receptor Antagonists
    • Glutamate Modulators
    • Serotonin Dopamine Activity Modulators
  • Formulation Type
    • Inserts and Patches
    • Liquid Solutions
    • Solid Tablets
  • End Users
    • Homecare Settings
    • Hospitals
    • Mental Health Clinics
    • Research Institutes
  • Patient Settings
    • Inpatient Care
    • Outpatient Care
  • Patient Demographics
    • Adult Patients
    • Geriatric Patients
    • Pediatric Patients
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
      • Massachusetts
      • North Carolina
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • AbbVie Inc.
  • Acadia Pharmaceuticals Inc.
  • Alkermes Plc
  • Amneal Pharmaceuticals, LLC
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • BioXcel Therapeutics, Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Company
  • Cipla Limited
  • Delpor, Inc.
  • Dr. Reddy’s Laboratories Ltd.
  • Eli Lilly and Company
  • Gedeon Richter Plc
  • GlaxoSmithKline plc.
  • Glenmark Pharmaceuticals Limited
  • Johnson & Johnson Services, Inc.
  • Lundbeck A/S
  • Lupin Limited
  • Luye Pharma Group Ltd
  • Lyndra Therapeutics Inc
  • Meiji Holdings Co., Ltd.
  • Merck & Co., Inc.
  • Neurocrine Biosciences, Inc.
  • Novartis AG
  • Otsuka Holdings Co., Ltd.
  • Pfizer Inc.
  • Reviva Pharmaceuticals Holdings, Inc.
  • Sanofi S.A
  • Sumitomo Pharma Co., Ltd.
  • Sun Pharmaceutical Industries Limited
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Vanda Pharmaceuticals Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Schizophrenia Therapeutics Market, by Type
8.1. Introduction
8.2. Non-Pharmacological Therapies
8.2.1. Cognitive-Behavioral Therapy (CBT)
8.2.2. Electroconvulsive Therapy (ECT)
8.2.3. Family Therapy
8.3. Pharmacological Therapies
8.3.1. Injectable Medications
8.3.2. Oral Medications
9. Schizophrenia Therapeutics Market, by Therapeutic Class
9.1. Introduction
9.2. Antipsychotics
9.2.1. First-Generation Antipsychotics
9.2.2. Second-Generation Antipsychotics
9.3. Mood Stabilizers
9.4. Selective Serotonin Reuptake Inhibitors
10. Schizophrenia Therapeutics Market, by Mechanism of Action
10.1. Introduction
10.2. Dopamine Receptor Antagonists
10.3. Glutamate Modulators
10.4. Serotonin Dopamine Activity Modulators
11. Schizophrenia Therapeutics Market, by Formulation Type
11.1. Introduction
11.2. Inserts and Patches
11.3. Liquid Solutions
11.4. Solid Tablets
12. Schizophrenia Therapeutics Market, by End Users
12.1. Introduction
12.2. Homecare Settings
12.3. Hospitals
12.4. Mental Health Clinics
12.5. Research Institutes
13. Schizophrenia Therapeutics Market, by Patient Settings
13.1. Introduction
13.2. Inpatient Care
13.3. Outpatient Care
14. Schizophrenia Therapeutics Market, by Patient Demographics
14.1. Introduction
14.2. Adult Patients
14.3. Geriatric Patients
14.4. Pediatric Patients
15. Americas Schizophrenia Therapeutics Market
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. Argentina
16. Europe, Middle East & Africa Schizophrenia Therapeutics Market
16.1. Introduction
16.2. United Kingdom
16.3. Germany
16.4. France
16.5. Russia
16.6. Italy
16.7. Spain
16.8. United Arab Emirates
16.9. Saudi Arabia
16.10. South Africa
16.11. Denmark
16.12. Netherlands
16.13. Qatar
16.14. Finland
16.15. Sweden
16.16. Nigeria
16.17. Egypt
16.18. Turkey
16.19. Israel
16.20. Norway
16.21. Poland
16.22. Switzerland
17. Asia-Pacific Schizophrenia Therapeutics Market
17.1. Introduction
17.2. China
17.3. India
17.4. Japan
17.5. Australia
17.6. South Korea
17.7. Indonesia
17.8. Thailand
17.9. Philippines
17.10. Malaysia
17.11. Singapore
17.12. Vietnam
17.13. Taiwan
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. AbbVie Inc.
18.3.2. Acadia Pharmaceuticals Inc.
18.3.3. Alkermes Plc
18.3.4. Amneal Pharmaceuticals, LLC
18.3.5. Astellas Pharma Inc.
18.3.6. AstraZeneca plc
18.3.7. BioXcel Therapeutics, Inc.
18.3.8. Boehringer Ingelheim International GmbH
18.3.9. Bristol Myers Squibb Company
18.3.10. Cipla Limited
18.3.11. Delpor, Inc.
18.3.12. Dr. Reddy’s Laboratories Ltd.
18.3.13. Eli Lilly and Company
18.3.14. Gedeon Richter Plc
18.3.15. GlaxoSmithKline plc.
18.3.16. Glenmark Pharmaceuticals Limited
18.3.17. Johnson & Johnson Services, Inc.
18.3.18. Lundbeck A/S
18.3.19. Lupin Limited
18.3.20. Luye Pharma Group Ltd
18.3.21. Lyndra Therapeutics Inc
18.3.22. Meiji Holdings Co., Ltd.
18.3.23. Merck & Co., Inc.
18.3.24. Neurocrine Biosciences, Inc.
18.3.25. Novartis AG
18.3.26. Otsuka Holdings Co., Ltd.
18.3.27. Pfizer Inc.
18.3.28. Reviva Pharmaceuticals Holdings, Inc.
18.3.29. Sanofi S.A
18.3.30. Sumitomo Pharma Co., Ltd.
18.3.31. Sun Pharmaceutical Industries Limited
18.3.32. Takeda Pharmaceutical Company Limited
18.3.33. Teva Pharmaceutical Industries Ltd.
18.3.34. Torrent Pharmaceuticals Ltd.
18.3.35. Vanda Pharmaceuticals Inc.
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. SCHIZOPHRENIA THERAPEUTICS MARKET MULTI-CURRENCY
FIGURE 2. SCHIZOPHRENIA THERAPEUTICS MARKET MULTI-LANGUAGE
FIGURE 3. SCHIZOPHRENIA THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2030 (%)
FIGURE 10. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2024 VS 2030 (%)
FIGURE 16. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2024 VS 2030 (%)
FIGURE 18. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2030 (%)
FIGURE 20. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 24. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. SCHIZOPHRENIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 30. SCHIZOPHRENIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. SCHIZOPHRENIA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COGNITIVE-BEHAVIORAL THERAPY (CBT), BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ELECTROCONVULSIVE THERAPY (ECT), BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FAMILY THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY INJECTABLE MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ORAL MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FIRST-GENERATION ANTIPSYCHOTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SECOND-GENERATION ANTIPSYCHOTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY GLUTAMATE MODULATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SEROTONIN DOPAMINE ACTIVITY MODULATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY INSERTS AND PATCHES, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY LIQUID SOLUTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SOLID TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY INPATIENT CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY OUTPATIENT CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY GERIATRIC PATIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 65. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 66. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 67. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 68. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 69. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
TABLE 70. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 71. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 72. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 73. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 74. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 75. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 76. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 77. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 78. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 79. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
TABLE 80. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 81. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 82. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 83. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 84. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 94. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 116. UNITED KINGDOM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 117. UNITED KINGDOM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 118. UNITED KINGDOM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 119. UNITED KINGDOM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 120. UNITED KINGDOM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
TABLE 121. UNITED KINGDOM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 122. UNITED KINGDOM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 123. UNITED KINGDOM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 124. UNITED KINGDOM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 125. UNITED KINGDOM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 126. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 127. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 128. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 129. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 130. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
TABLE 131. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 132. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 133. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 134. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 135. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 136. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 137. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 138. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 139. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 140. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
TABLE 141. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 142. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 143. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 144. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 145. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 146. RUSSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 147. RUSSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 148. RUSSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 149. RUSSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 150. RUSSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
TABLE 151. RUSSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 152. RUSSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 153. RUSSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 154. RUSSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 155. RUSSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 156. ITALY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 157. ITALY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 158. ITALY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 159. ITALY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 160. ITALY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
TABLE 161. ITALY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 162. ITALY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 163. ITALY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 164. ITALY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 165. ITALY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 166. SPAIN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 167. SPAIN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 168. SPAIN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 169. SPAIN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 170. SPAIN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
TABLE 171. SPAIN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 172. SPAIN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 173. SPAIN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 174. SPAIN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 175. SPAIN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 176. UNITED ARAB EMIRATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 177. UNITED ARAB EMIRATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 178. UNITED ARAB EMIRATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 179. UNITED ARAB EMIRATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 180. UNITED ARAB EMIRATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
TABLE 181. UNITED ARAB EMIRATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 182. UNITED ARAB EMIRATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 183. UNITED ARAB EMIRATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 184. UNITED ARAB EMIRATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 185. UNITED ARAB EMIRATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 186. SAUDI ARABIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 187. SAUDI ARABIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 188. SAUDI ARABIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 189. SAUDI ARABIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 190. SAUDI ARABIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
TABLE 191. SAUDI ARABIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 192. SAUDI ARABIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 193. SAUDI ARABIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 194. SAUDI ARABIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 195. SAUDI ARABIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 196. SOUTH AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 197. SOUTH AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 198. SOUTH AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 199. SOUTH AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 200. SOUTH AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
TABLE 201. SOUTH AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 202. SOUTH AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 204. SOUTH AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 205. SOUTH AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 206. DENMARK SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 207. DENMARK SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 208. DENMARK SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 209. DENMARK SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 210. DENMARK SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
TABLE 211. DENMARK SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 212. DENMARK SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 213. DENMARK SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 214. DENMARK SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 215. DENMARK SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 216. NETHERLANDS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 217. NETHERLANDS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 218. NETHERLANDS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 219. NETHERLANDS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 220. NETHERLANDS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
TABLE 221. NETHERLANDS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 222. NETHERLANDS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 223. NETHERLANDS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 224. NETHERLANDS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 225. NETHERLANDS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 226. QATAR SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 227. QATAR SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 228. QATAR SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 229. QATAR SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 230. QATAR SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
TABLE 231. QATAR SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 232. QATAR SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 233. QATAR SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 234. QATAR SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 235. QATAR SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 236. FINLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 237. FINLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 238. FINLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 239. FINLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 240. FINLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
TABLE 241. FINLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 242. FINLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 243. FINLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 244. FINLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 245. FINLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 246. SWEDEN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 247. SWEDEN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 248. SWEDEN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 249. SWEDEN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 250. SWEDEN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
TABLE 251. SWEDEN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 252. SWEDEN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 253. SWEDEN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 254. SWEDEN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 255. SWEDEN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 256. NIGERIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 257. NIGERIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 258. NIGERIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 259. NIGERIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 260. NIGERIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
TABLE 261. NIGERIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 262. NIGERIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 263. NIGERIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 264. NIGERIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 265. NIGERIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 266. EGYPT SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 267. EGYPT SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 268. EGYPT SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 269. EGYPT SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 270. EGYPT SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
TABLE 271. EGYPT SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 272. EGYPT SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 273. EGYPT SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 274. EGYPT SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 275. EGYPT SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 276. TURKEY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 277. TURKEY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 278. TURKEY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 279. TURKEY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 280. TURKEY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
TABLE 281. TURKEY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 282. TURKEY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 283. TURKEY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 284. TURKEY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 285. TURKEY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 286. ISRAEL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 287. ISRAEL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 288. ISRAEL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 289. ISRAEL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 290. ISRAEL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
TABLE 291. ISRAEL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 292. ISRAEL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 293. ISRAEL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 294. ISRAEL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 295. ISRAEL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 296. NORWAY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 297. NORWAY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 298. NORWAY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 299. NORWAY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 300. NORWAY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
TABLE 301. NORWAY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 302. NORWAY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 303. NORWAY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 304. NORWAY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
TABLE 305. NORWAY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 306. POLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 307. POLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON

Companies Mentioned

The companies profiled in this Schizophrenia Therapeutics market report include:
  • AbbVie Inc.
  • Acadia Pharmaceuticals Inc.
  • Alkermes Plc
  • Amneal Pharmaceuticals, LLC
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • BioXcel Therapeutics, Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Company
  • Cipla Limited
  • Delpor, Inc.
  • Dr. Reddy’s Laboratories Ltd.
  • Eli Lilly and Company
  • Gedeon Richter Plc
  • GlaxoSmithKline plc.
  • Glenmark Pharmaceuticals Limited
  • Johnson & Johnson Services, Inc.
  • Lundbeck A/S
  • Lupin Limited
  • Luye Pharma Group Ltd
  • Lyndra Therapeutics Inc
  • Meiji Holdings Co., Ltd.
  • Merck & Co., Inc.
  • Neurocrine Biosciences, Inc.
  • Novartis AG
  • Otsuka Holdings Co., Ltd.
  • Pfizer Inc.
  • Reviva Pharmaceuticals Holdings, Inc.
  • Sanofi S.A
  • Sumitomo Pharma Co., Ltd.
  • Sun Pharmaceutical Industries Limited
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Vanda Pharmaceuticals Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages183
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 6.21 Billion
Forecasted Market Value ( USD ) by 2030 $ 8.12 Billion
Compound Annual Growth Rate5.4%
Regions CoveredGlobal
No. of Companies Mentioned36

Related Topics

Related Reports

Schizophrenia Drugs Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033 - Product Image

Schizophrenia Drugs Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033

  • Report
  • 200 Pages
  • Global
From
Schizophrenia Therapeutics - Global Strategic Business Report - Product Image

Schizophrenia Therapeutics - Global Strategic Business Report

  • Report
  • 197 Pages
  • Global
From
Schizophrenia Drugs Market Size, Share and Trends Analysis Report by Class (Second-Generation Antipsychotics, Third-Generation Antipsychotics, Others), Treatment, Distribution Channels, and Region 2024-2030 - Product Image

Schizophrenia Drugs Market Size, Share and Trends Analysis Report by Class (Second-Generation Antipsychotics, Third-Generation Antipsychotics, Others), Treatment, Distribution Channels, and Region 2024-2030

  • Report
  • 100 Pages
  • Global
From
Antipsychotic Drugs - Global Strategic Business Report - Product Image

Antipsychotic Drugs - Global Strategic Business Report

  • Report
  • 193 Pages
  • Global
From
Schizophrenia: Seven-Market Drug Forecast and Market Analysis - Update - Product Image

Schizophrenia: Seven-Market Drug Forecast and Market Analysis - Update

  • Report
  • 144 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.